Skip to main content

Acute Pain, Postoperative

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
LTG-001 High DosePhase 21 trial
Active Trials
NCT06774625Completed250Est. Aug 2025
Latigo Biotherapeutics
Latigo BiotherapeuticsCA - Thousand Oaks
1 program
LTG-001 High DosePHASE_2

Trial Timeline

Clinical trial activity over time

2024
2025
2026
BioTherapeutics IncLTG-001 High Dose

Clinical Trials (1)

Total enrollment: 250 patients across 1 trials

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

Start: Dec 2024Est. completion: Aug 2025250 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.